60 results about "Proteinuria" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The present invention discloses a traditional Chinese medicine composition for treating chronic kidney disease, its preparation method, and application, belonging to the technical field of traditional Chinese medicine preparation. The composition is prepared from the following raw materials in parts by weight: 25-40 parts of astragalus, 25-35 parts of raw rehmannia, 25-35 parts of prepared rehmannia, 27-33 parts of ligusticum, 10-20 parts of euryale, 10-20 parts of rosa laevigata fruit, 18-25 parts of cornus fruit with wine, 13-20 parts of schisandra chinensis with vinegar, 10-15 parts of ligustrum lucidum fruit, and 10-15 parts of eclipta. The traditional Chinese medicine composition provided by the present invention has a significant therapeutic effect on patients with chronic kidney disease suffering from kidney deficiency and blood stasis syndrome, characterized by edema, lumbago, fatigue, proteinuria, hematuria, and the like.

The invention discloses a walnut-derived xanthine oxidase inhibitory peptide and application thereof, and belongs to the technical field of bioactive peptide biology. The amino acid sequence of the xanthine oxidase inhibitory peptide provided by the invention is as shown in SEQ ID No. 1. Through in-vitro activity determination, the IC50 value of the inhibitory peptide is 3.34 mg / mL, and it is proved that the inhibitory peptide has high inhibitory activity on xanthine oxidase. Besides, the inhibitory peptide can reduce the levels of creatinine, urea nitrogen, adenosine deaminase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, regulate the expression of kidney uric acid resorption protein URAT1, uric acid excretion protein GLUT9 and ABCG2, and significantly reduce the generation of uric acid, can be used for inhibiting xanthine oxidase and preventing or improving hyperuricemia, is applied to preparation of drugs for improving hyperuricemia, and has broad application prospects. The medicine takes the active peptide as the only active ingredient or one of the active ingredients, and has a good application prospect.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The embodiment of the present specification provides an antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease, the antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region. Wherein, the heavy chain variable region comprises CDRH1 of an amino acid sequence as shown in SEQ ID NO: 2, CDRH2 of an amino acid sequence as shown in SEQ ID NO: 3 and CDRH of an amino acid sequence as shown in SEQ ID NO: 4. The light chain variable region comprises CDRL1 of an amino acid sequence as shown in SEQ ID NO: 6, CDRL2 of an amino acid sequence of DTS and CDRL3 of an amino acid sequence as shown in SEQ ID NO: 7. The antibody or antigen binding fragment has the characteristics of high purity, high specificity and sensitivity. The embodiment of the present specification also provides related application of the antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease.

Provided is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the IgA nephropathy by means of a liquid biopsy of blood other than a highly invasive kidney biopsy or conventionally used proteinuria or hematuria. The present invention is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the disease in a subject animal, said method comprising the steps of: (a) measuring an IgA nephropathy marker protein contained in an IgA immune complex in a blood sample collected from the subject animal; and (b) determining the likelihood of the onset or the activity of the IgA nephropathy in the test animal on the basis of the amount of the IgA nephropathy marker protein, which is a protein contained in an IgA immune complex, measured in the step (a), the IgA nephropathy marker protein being a protein contained in an IgA immune complex, and the IgA nephropathy marker protein being a protein contained in an IgA immune complex. The content of the IgA immune complex in the group of IgA nephropathy patients is greater than the content of the IgA immune complex in the group of healthy persons.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The present invention relates to novel polymorphic forms of Iptacopan hydrochloride and preparation thereof. The invention also relates to pharmaceutical composition comprising novel polymorphic forms of Iptacopan hydrochloride and their use in the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.

Methods for treating high proteinuria chronic kidney disease and / or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

The invention discloses a traditional Chinese medicine composition for treating idiopathic membranous nephropathy and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 12-45 parts of radix astragali (raw), 10-15 parts of radix stephaniae tetrandrae, 10-20 parts of angelica sinensis, 10-20 parts of radix paeoniae alba, 10-15 parts of ligusticum wallichii, 10-15 parts of peach kernels, 10-30 parts of rhizoma atractylodis macrocephalae (fried), 10-15 parts of rhizoma alismatis, 10-30 parts of poria cocos, 15-30 parts of rhizoma dioscoreae nipponicae, 15-30 parts of oldenlandia diffusa and 9-30 parts of plantain herb. Pharmacodynamic experiments prove that the radix astragali, radix angelicae sinensis and radix paeoniae alba formula has an obvious improvement effect on membranous nephropathy experimental models and related edema, proteinuria and renal functions of idiopathic membranous nephropathy patients.

The invention relates to the technical field of biological medicine, in particular to application of a pharmaceutical composition in preparation of a medicine for treating diabetic nephropathy, the pharmaceutical composition is composed of active ingredients and pharmaceutically acceptable auxiliary materials, and the pharmaceutical composition is characterized in that the active ingredients are selected from the group consisting of active ingredients and pharmaceutically acceptable auxiliary materials; the active component is selected from one or more of melibiose or pharmaceutically acceptable salt, isomer and precursor thereof. The melibiose disclosed by the invention has the advantages that the melibiose can obviously improve diabetic mouse glomerular endothelial cell injury, reduce proteinuria, improve inflammation and play a role in protecting kidneys.

The present invention provides a device for detecting an analyte in a liquid sample, the device comprising: a test element for testing whether the analyte exists in the liquid sample or the number of the analyte, the analyte being one or more of the following analyte: neopterin; the amino acid sequence is shown in the description, and the amino acid sequence is shown in the description. The invention relates to a preparation method of a graphene oxide-dopamine composite material. The invention also relates to a method for preparing the microalbuminuria. The microalbuminuria is prepared from the microalbuminuria.

The application discloses a method for constructing a rat passive Heymann nephritis model, and belongs to the technical field of biological medicines, and comprises the following steps: injecting a rat with Sheep Anti-Rat Fx1A Serum through a tail vein for multiple times with an interval of 24 hours. The rat PHN model is successfully constructed by twice tail vein injection of the rat with the Sheep Anti-Rat Fx1A Serum, the model rat shows the nephrotic syndrome characterized by a large amount of proteinuria, the disease course is long, the disease condition is not easy to relieve, and the long-term observation requirement can be met. The modeling method is simple and easy to realize, and can provide research help for dynamic observation of kidney damage of the model animal, discussion of the pathogenesis of the PHN and research and development of drug treatment of the human model nephropathy.

The utility model discloses a urine formation dynamic demonstration instrument capable of segmentally demonstrating, which comprises a nephrology main body structure model, a display board bracket, a solution collector, a circulating water pump, an appendage part and a liquid simulation part, the renal unit main body structure model comprises a glomerulus model, a renal capsule model, a renal tubule model, a filter screen, a globular arteriole model, a globular arteriole model, a renal vein model and a capillary model; the filter screen is embedded at the bottom of a sphere of the glomerular model; the glomerulus model, the kidney capsule model, the bulblet arteriole model and the capillary model penetrate through the display board bracket and extend to the corresponding solution collectors; wherein one end of one renal tubule model passes through the display board bracket and extends to the corresponding solution collector, and the other end extends to the corresponding solution collector on the front side of the display board bracket. According to the utility model, not only can the urine formation process be visually demonstrated, but also students can understand the occurrence mechanism of diseases such as proteinuria and hematuria caused by urinary organ abnormity.

The invention discloses a biomarker for detecting renal fibrosis, application and a system, and relates to the technical field of biological medicines. The invention relates to a biomarker for detecting renal fibrosis. The biomarker comprises urinary copper cyanin. Compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin has the following three advantages: 1, compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin is more sensitive to diagnosis of renal interstitial fibrosis and fibrosis severity; secondly, compared with traumatic renal tissue pathologic biopsy, urine is used as a diagnosis medium, so that true noninvasive effect can be realized, and no harm is caused to the body health of a patient; and thirdly, compared with detection means such as iconography, the method for detecting the urinary cupreocyanin marker is lower in cost, more flexible, high in timeliness and easier to popularize.

The traditional Chinese medicine composition disclosed by the invention adopts a method of warming yang and relieving exterior syndrome to achieve the effects of freeing lung and inducing diuresis, tonifying spleen and warming kidney, and strengthening defensive qi and diminishing swelling, and is prepared to be used for treating the immune-related glomerular diseases, especially membranous nephropathy and minimal lesion nephropathy. The traditional Chinese medicine composition is a pure traditional Chinese medicine preparation, clinical observation and in-vivo and in-vitro basic tests show that the prescription can remarkably improve edema, massive proteinuria, hypoproteinemia and the like, meanwhile, compared with the prior art, the traditional Chinese medicine composition has a better effect on symptoms such as stomachache and diarrhea, has an anti-inflammatory effect and does not have obvious side effects in clinical application. The traditional Chinese medicine composition has an excellent effect on patients suffering from membranous nephropathy and minimal lesion nephropathy caused by syndrome differentiation of spleen-kidney yang deficiency, internal rheumatism and water-fluid overflowing.

An example embodiment may involve obtaining, by a computing system, an observation of demographic values of an individual, vital sign values of the individual, and blood test values of the individual: applying, by the computing system, a machine learning model to the observation, wherein the machine learning model was trained with a training data set, wherein the training data set contained observations of corresponding demographic values, vital sign values, blood test values, and either urine albumin-to-creatinine ratio (UACR) values or urine protein-to-creatinine ratio (UPR) values for a plurality of individuals, and wherein the machine learning model is configured to provide predictions of whether further observations are indicative of undiagnosed albuminuria or proteinuria; and providing, by the computing system, a prediction of whether the individual exhibits undiagnosed albuminuria or proteinuria based on the observation.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

This application discloses the application of uridine phosphorylase 1 (UPP1) as an inhibitory target in the preparation of drugs for treating systemic lupus erythematosus (SLE), relating to the field of biomedical technology. This application is the first to discover abnormally elevated UPP1 expression in peripheral blood mononuclear cells of SLE patients, which is positively correlated with disease activity. Validation experiments demonstrate that the specific inhibitor of UPP1, BAU, can effectively inhibit UPP1 enzyme activity. In cell models, it reduces inflammatory factors and type I interferon responses induced by STING pathway activation. In SLE animal models, BAU significantly reduces splenomegaly, proteinuria, and pathological damage to the kidneys and lungs, decreases the proportion of pathogenic immune cells such as M1 macrophages, Th1 cells, and plasma cells in the spleen, and inhibits the deposition of immune complexes in the glomeruli. This invention reveals for the first time the potential of UPP1 as a novel therapeutic target for SLE and provides BAU as a candidate drug for treating SLE and related organ damage, offering a novel strategy for clinical intervention.

The invention discloses a traditional Chinese medicine composition for treating targeted drug related proteinuria, a pharmaceutical preparation and application. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials or extracts thereof: angelica sinensis, radix paeoniae alba, raw astragalus membranaceus, radix pseudostellariae, radix ophiopogonis, schisandra chinensis, raw atractylodes macrocephala koidz and divaricate saposhnikovia roots. The traditional Chinese medicine composition treats the anti-angiogenesis targeted drug related proteinuria through the treatment rules of activating blood and nourishing liver, and invigorating spleen and tonifying kidney, so that the patients can be treated by drugs, and the risk of drug withdrawal of the hepatocellular carcinoma patients due to the anti-angiogenesis targeted drug related proteinuria such as a vascular endothelial growth factor inhibitor is further reduced; the long-term prognosis of hepatocellular carcinoma patients is improved, and the lifetime of the hepatocellular carcinoma patients is prolonged.

After several years of illness, a small amount of albumin in the blood of nephritis patients will begin to leak into the urine. At this time, it is easily overlooked due to the insignificant clinical symptoms or being confused with proteinuria caused by other factors such as hypertension and hyperlipidemia, leading to the progression of the disease. However, when it is found that other indicators reflecting renal function, such as β2-microglobulin, α1-microglobulin, transferrin, and immunoglobulin, are also significantly elevated in the urine, it can be confirmed that pathological changes have occurred in renal function. Currently, there is no other effective treatment method except for hormones, and long-term hormone treatment will bring many side effects to patients. If the disease progresses freely, more proteins will leak into the urine and the kidney damage will further increase. Cobra neurotoxin polypeptide molecules can effectively reduce the leakage of the above various proteins in the urine, control and delay the pathological progression of the kidney, improve renal function, and are of extremely important significance for the treatment of nephritis by inhibiting the autoimmune inflammatory reaction of the kidney.

The invention discloses a method for constructing a spontaneous systemic lupus erythematosus animal model, which comprises the following steps: knocking out EP300 (E1A Binding Protein P300) in keratinocytes to enable a mouse to spontaneously have systemic lupus erythematosus phenotypes, including local skin unhairing, persistent skin lesion, persistent proteinuria and serum autoantibodies; the systemic lupus erythematosus sample changes such as dermal immune cell infiltration and glomerular IgG deposition exist in histological examination, clinical symptoms of systemic lupus erythematosus are simulated, and an important tool is provided for related research of systemic lupus erythematosus.

Collapsing focal segmental glomerulosclerosis (collapsing FSGS), also known as collapsing glomerulopathy (CG), is the most aggressive variant of FSGS and is characterized by rapid progression to end-stage kidney disease (ESKD). The inventors used the telomerase-induced mouse model of CG (i-TERTci mice) to identify mechanisms to inhibit CG pathogenesis. They found that inactivation of WIP1 phosphatase, a p53 target acting in a negative feedback loop, blocks disease initiation in i-TERTci mice. They found that pharmacologic inhibition of WIP1 enzymatic activity in either telomerase mice with CG or in Tg26 mice promotes partial remission of proteinuria and ameliorates renal histopathologic features. Their findings suggest that targeting WIP1 may be an effective therapeutic strategy for patients with CG. Thus, the present invention relates to a method of preventing or treating glomerular disease (e.g. focal segmental glomerulosclerosis, in particular collapsing glomerulopathy) in a subject in need thereof, comprising the step of administering to said subject a Wild-type p53-induced phosphatase 1 (WIP1) inhibitor.

The invention discloses a traditional Chinese medicine composition for preventing and treating pregnancy complications as well as a preparation method and application thereof. The composition is composed of medicinal and edible traditional Chinese medicines including radix rehmanniae recen, fructus gardeniae, gastrodia elata, fructus lycii and exocarpium citri rubrum, and mulberry leaves, ramulus uncariae cum uncis and the like can be selectively added. The preparation method comprises the steps of extracting volatile oil by steam distillation, leaching by a solvent, concentrating, mixing and the like, and can be combined with ultrasonic crushing to strengthen extraction. The composition is based on the treatment method of nourishing kidney, containing wood, clearing heat, calming liver, dissolving turbidity and preventing miscarriage in traditional Chinese medicine, has the effects of multi-target synergistic pressure reduction, proteinuria improvement and fetal development promotion aiming at the pathogenesis of yin deficiency and yang hyperactivity in the gestation period, is high in safety and free of fetal toxic and side effects, and is suitable for prevention and treatment of hypertensive diseases in the gestation period such as preeclampsia and the like.

Disclosed are methods for treating high proteinuria chronic kidney disease and / or at least one disease, disorder or condition associated therewith in a patient by using a fixed dose combination of zipotentan and dapagliflozin.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.